What PRODROMIC LTD does

Prodromic Limited is a Cambridge-based AI spin-out from the University of Cambridge that develops a multimodal AI platform for early dementia prediction and patient stratification. Its core technology fuses cognitive tests, health records, structural MRI and PET imaging, genetics (APOE4), blood biomarkers (including Ptau217), and proteomic signals into interpretable patient-level trajectory scores. Models are validated on more than 20,000 patients across 11 global datasets spanning North America, Europe, and Asia, with peer-reviewed evidence in Nature Communications, The Lancet: eClinicalMedicine, and Neuroimage: Clinical, and claimed performance of threefold higher sensitivity than standard approaches at baseline.

The commercial offering consists of an end-to-end SaaS platform and a modular library of ready-to-use AI engines that can be configured for different workflows, from low-cost screening to biomarker-rich precision clinical trials. The company explicitly positions its solutions as research tools rather than regulated medical devices, indicating a research-use commercialization path before any clinical-decision-support deployment. Revenue is generated through platform subscriptions and likely usage-based fees, though no pricing is publicly disclosed.

Prodromic's go-to-market is B2B enterprise, targeting pharmaceutical developers as the primary segment to accelerate and de-risk clinical trials, with secondary motion into clinicians and healthcare systems for early triage and treatment planning. It is founder-led by Professor Zoe Kourtzi (CSO) and Andrew Welchman PhD (CEO), and operates from Milton Hall, Cambridge, with a current team of 1–10 employees and no disclosed venture funding to date.

Name

PRODROMIC LTD

Legal name

Prodromic Limited

Website

https://prodromic.ai

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Prodromic Ltd is a Cambridge spin-out from the University of Cambridge building a multimodal AI platform for early dementia prediction and patient stratification. It serves pharmaceutical developers, clinicians, and healthcare systems with a SaaS research tool validated on 20,000+ patients.

Ownership category

akta.pro rank

Product category

AI-Powered Clinical Predictive Analytics

NAICS

Software Publishers (513210), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Medical Imaging AI (HDAAAEAH), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)

Keywords

• AI dementia prediction
• Clinical trial stratification
• Multimodal medical AI
• Brain health analytics
• Patient stratification software

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. SaaS Platform Subscription: End-to-end SaaS solution providing predictive analytics. Platform processes input data and outputs patient-level predictive scores. Revenue likely generated through platform access and usage fees.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Prodromic provides an end-to-end multimodal AI SaaS platform for early dementia prediction and patient stratification. It ingests cognitive tests, health records, imaging (structural MRI, PET), blood biomarkers (e.g., Ptau217), genetics (APOE4), and proteomic signals to produce interpretable, patient-level scores predicting disease trajectory. A library of ready-to-use AI engines can be deployed across workflows ranging from low-cost screening to biomarker-rich precision clinical trials, helping pharma and clinical partners accelerate trials and improve diagnostic accuracy.

Product overview

Prodromic offers a unified multimodal AI platform for early dementia prediction. The core Prodromic AI Platform is an end-to-end SaaS solution that processes diverse clinical data sources and outputs interpretable disease trajectory scores. This platform is supported by a library of ready-to-use AI engines trained on different combinations of features, allowing flexible deployment across different clinical workflows—from screening to precision clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Prodromic AI Platform End-to-end SaaS platform that ingests multimodal clinical data (cognitive tests, health records, imaging, blood biomarkers, genetics, proteomic signals), identifies biologically- and clinically-relevant signals, builds predictions, and outputs easy-to-interpret patient-level scores for dementia trajectory. Targets pharmaceutical developers, clinicians, and healthcare systems for trial design, early triage, and treatment planning.
• AI Engine Library

Quantifiable outcome

• Threefold higher sensitivity than standard approaches for distinguishing patient trajectories at baseline
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Clinicians and Healthcare ProviderscoreStrategic or Co-development PartnerWorking with clinicians to accelerate the fight against brain diseases by identifying suitable patients earlier in disease. Focus on embedding AI tools into clinical workflows to improve early triage and treatment outcomes.
• Academic InstitutionscoreStrategic or Co-development PartnerCollaboration with academic researchers to accelerate new treatments and generate better biological insights into brain health. Based on decade of research from University of Cambridge.
• Pharmaceutical DeveloperscoreStrategic or Co-development PartnerPartnership with pharma developers to accelerate clinical trials by identifying suitable patients earlier. Prodromic's technology makes trials faster, lower-cost, and more effective by enabling better patient stratification.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cambridge Cognition: UK-based neuroscience-focused company (CANTAB) providing computerised cognitive assessments and digital biomarkers widely used in pharma-sponsored dementia and CNS clinical trials — highly comparable use case (trial stratification) and product category.
• IXICO: UK-based neuroimaging analytics company providing AI-enabled MRI/PET analysis and biomarker services for neurodegenerative disease clinical trials — comparable imaging-AI capability and pharma-trial customer base.
• Cogstate: Commercial-stage digital cognition company offering computerised tests for use in clinical trials (notably Alzheimer's and other CNS indications) and healthcare — directly overlapping product offering (cognitive testing for trials) and target customers (pharma developers).
• Altoida: US/Swiss digital neurology company using AR-based assessments and AI/ML to generate digital biomarkers predicting conversion from MCI to Alzheimer's — overlapping patient-stratification and clinical-trial use case in the dementia space.
• Linus Health: Boston-based digital health company combining AI-driven digital cognitive assessments (e.g., DCTclock, voice-based tests) with multi-modal data for early brain health evaluation, clinical trial stratification, and dementia risk detection — directly comparable offering and customer base (pharma + clinicians).
• Cumulus Neuroscience: UK-based neuroscience platform combining at-home digital cognitive testing, speech, and physiology data with analytics to generate biomarkers for CNS clinical trials — comparable multi-modal patient-stratification offering for pharma trials.

Broad incumbents

• Clario (formerly Bioclinica): Large clinical-trial technology vendor offering imaging, eCOA, and CNS/neurodegenerative trial services across pharma — overlapping customer base and broad portfolio including imaging analytics used for trial stratification.

Emerging players

• Darmiyan: US-based AI neuroimaging company (BrainSee) using non-invasive MRI to predict Alzheimer's disease onset years before symptoms — overlapping multi-modal imaging AI approach and dementia focus, but earlier-stage and narrower modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/prodromic

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PRODROMIC LTD